HUMMELSTOWN, Pa., July 24, 2025–(BUSINESS WIRE)–Targepeutics, a biotech company dedicated to developing targeted therapies for aggressive pediatric brain cancers, is proud to announce a strategic financing round led by the Yuvaan Tiwari Foundation. This investment will directly support the advancement of GB13, Targepeutics’ lead drug candidate, into clinical trials for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) — one of the deadliest pediatric brain tumors.
“We are honored to welcome the Yuvaan Tiwari Foundation into the Targepeutics community,” said Sil Lutkewitte, CEO of Targepeutics. “Their support is more than just financial — it represents a deep, shared commitment to pushing forward the science and bringing hope to families facing DIPG.”
GB13 is a first-in-class precision therapy designed to target a key molecular driver of DIPG….
